FDA inspection
3D Imaging Drug Design and Development: FDA inspection ending Jan 18, 2019
FDA inspection 1076821 · Voluntary Action Indicated (VAI) · Little Rock, AR
Key facts
| Inspection ID | 1076821 |
|---|---|
| Firm | 3D Imaging Drug Design and Development |
| FEI number | 3009143510 |
| Address | 9015 Carti Way |
| City | Little Rock |
| State | AR |
| ZIP | 72205 |
| Fiscal year | 2019 |
| Inspection end date | Jan 18, 2019 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Generic Drug Evaluation |
| Product type | Drugs |
At a glance
- 1–9 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- Yes Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data